PubMed HealthSearch

PubMed · 7912833

Molecular modeling methods. Basic techniques and challenging problems.

Abstract

An overview is presented of computer modeling and simulation methods that play an increasing role in drug design: quantum chemical methods, molecular mechanics, molecular dynamics and Brownian dynamics. The application of molecular dynamics for the prediction of thermodynamic properties like free energy differences and binding constants is discussed. The Brownian dynamics method is presented in connection with the calculation of effective electrostatic forces using the Poisson-Boltzmann equation, which allows one to sample ligand-binding geometries and to predict the kinetics of diffusion-limited enzyme reactions. New techniques that have recently been extensively developed, such as the global energy minimization and quantum-classical dynamics methods, are also introduced. The molecular modeling methods are illustrated with selected examples.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Lesyng, J A McCammon. 1993. Molecular modeling methods. Basic techniques and challenging problems.. https://doi.org/10.1016/0163-7258(93)90004-w

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Treatment of scleromyxedema with 2-chlorodeoxyadenosine.

Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.

Cladribine

2-Chloro-2'-deoxyadenosine (cladribine) and its analogues are good substrates and potent selective inhibitors of Escherichia coli purine-nucleoside phosphorylase.

2-Chloro-2'-deoxyadenosine (CldAdo), a nucleoside that has proven useful in the treatment of several chronic lymphoid malignancies, and its analogue, 2-bromo-2'-deoxyadenosine, are both effective inhibitors of the bacterial (Escherichia coli) purine-nucleoside phosphorylase (PNP), with Ki values of 4.5 microM and 6.3 microM, respectively. The examination of a series of base-modified analogues of CldAdo has shown that several other compounds have similar inhibitor properties, and has indicated that 6-benzyloxy-2-chloro-9-(2'-deoxy-beta-D-ribofuranosyl)purine is the most potent inhibitor with a Ki value of 0.5 microM, competitive with respect to inosine (Ino). CldAdo itself and its base-modified analogues, discounting those substituted at C(8), are also substrates for the E. coli PNP and undergo rapid glycosidic bond cleavage. CldAdo is degraded with substrate efficiency, i.e. Vmax/Km similar to that observed for Ino (130%), although the individual kinetic constants, Km and Vmax, are both approximately an order of magnitude lower than for Ino. All compounds tested are totally inactive as substrates and inhibitors for mammalian (calf spleen) PNP and therefore constitute a new class of potent selective, although cleavable, inhibitors of bacterial phosphorylases. 8-Bromo-2-chloro-2'-deoxyadenosine and 8-thio-2-chloro-2'-deoxyadenosine are the only base-modified CldAdo derivatives showing inhibitory activity against MOLT-3 (acute T-cell leukemia) and U-937 (histiocytic lymphoma) cells and, as shown in this study, are resistant to degradation by E. coli PNP. The above-mentioned results suggest that both analogues could be effective as oral cytotoxic agents that are noncleavable by enteric bacteria.

Cladribine